Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?

Francesco Ricci, Christophe Le Tourneau


Despite the considerable progresses and the high efficacy of adjuvant medical treatments (chemotherapy, hormonotherapy and targeted therapy) in early breast cancer, up to a third of breast cancer patients still recur and die (1). As breast cancer comprehends a large spectrum of different tumor phenotypes, some with a more indolent behavior and others, more aggressive, with a poor short-term outcome, a major clinical issue has arisen as how to handle patients with metastatic disease.